Syracuse R&D Tax Credit Explained for Businesses

R&D Tax Credits for Syracuse, New York Businesses

Syracuse, New York, is known for industries such as healthcare, education, manufacturing, technology, and retail. Top companies in the city include Upstate University Hospital, a leading healthcare provider; Syracuse University, a major educational institution; Lockheed Martin, a significant manufacturing employer; Anaren, a key player in the technology sector; and Destiny USA, a prominent retail complex. By reducing tax liability, businesses can reinvest in R&D, improve efficiency, and develop new products, enhancing their competitiveness and driving economic growth in Syracuse.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 350 Northern Blvd, Albany, New York is less than 150 miles away from Syracuse and provides R&D tax credit consulting and advisory services to Syracuse and the surrounding areas such as: Utica, Rome, Auburn, Oswego and Cortland.

If you have any questions or need further assistance, please call or email our local New York Partner on (518) 801-0616.
Feel free to book a quick teleconference with one of our New York R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Syracuse, New York Patent of the Year – 2024/2025

Zetagen Therapeutics Inc. has been awarded the 2024/2025 Patent of the Year for a breakthrough in localized cancer treatment. Their invention, detailed in U.S. Patent No. 11957676, titled ‘Controlled release formulation and minimally invasive method of administration to locally treat cancer’, delivers cancer-fighting agents directly to tumor sites using a novel formulation and administration method.

This innovation centers on a biodegradable, injectable compound that slowly releases therapeutic agents where they are needed most. Unlike traditional treatments that circulate through the entire body, Zetagen’s system minimizes damage to healthy tissue by concentrating its effect on the tumor itself.

The method allows for minimally invasive application, giving physicians more control over drug placement and reducing the need for repeated interventions. The formulation solidifies after injection, anchoring the treatment at the target site and ensuring sustained delivery over time.

This targeted approach has the potential to improve outcomes in difficult-to-treat cancers, such as bone or soft tissue tumors. It could also reduce side effects commonly associated with systemic therapies. For patients, that means better quality of life during treatment and a more focused battle against their disease.

Zetagen Therapeutics Inc. continues to lead in precision oncology, and this patent marks a major step forward in the use of controlled-release therapies to treat cancer with greater safety and effectiveness.